echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Sichuan pharmaceutical company will win over $10 billion in anticoagulant drugs

    Sichuan pharmaceutical company will win over $10 billion in anticoagulant drugs

    • Last Update: 2022-05-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    A few days ago, Chengdu Baiyu Pharmaceutical entered the administrative examination and approval stage with its generic apixaban tablets, which were reported for production in Category 4, and is expected to become the second antithrombotic drug that has been reviewed by the company


    Source: State Food and Drug Administration official website

    Apixaban is a potent, oral, reversible, direct and highly selective factor Xa active site inhibitor jointly developed by Pfizer and Bristol-Myers Squibb.


    Apixaban was first approved by the EMA in May 2011, approved by the FDA and PMDA in December 2012, and approved to enter the domestic market in January 2013.


    Global sales of apixaban

    Image source: Sales database of multinational listed companies on Minet.


    At present, there are more than 20 domestic enterprises that have the approval for the production of apixaban tablets, and the sales scale of this product in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) will break through in 2020.


    Review of Apixaban Tablets

    Source: Minet Consistency Evaluation Database

    According to the data of Minet.


    Some antithrombotic drugs deployed by Chengdu Baiyu Pharmaceutical Co.


    Source: MED2.


    In terms of antithrombotic drugs, Chengdu Baiyu Pharmaceutical submitted 3 generic drug marketing applications under new classifications, among which rivaroxaban tablets have been approved for production and are deemed to have been reviewed, and apixaban tablets are expected to become the company's second approved drug Reviewed antithrombotic drugs


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.